The Wall Street Journal: Akari Therapeutics CEO quits over retracted drug comparison

Akari Therapeutics PLC said Tuesday that its chief executive Dr. Gur Roshwalb, under fire over his involvement in the publication of a report that wrongfully claimed one of the company’s drugs was as good as a blockbuster drug on the market, resigned.

Roshwalb submitted his resignation Monday after an internal review found that, against company policy, he had reviewed and approved the report published by Edison Investment Research, Akari AKTX, -10.89% disclosed Tuesday in a securities filing.

The company couldn’t immediately be reached for comment.

Edison later retracted the report, which claimed that Akari’s lead candidate Coversin matched Alexion Pharmaceuticals Inc.

>>> Original Source <<<